Reappraisal of GIP Pharmacology for Metabolic Diseases

GIP, like GLP-1, is one of the predominant incretin hormones produced in the alimentary tract in response to food intake that function to lessen postprandial glucose excursions. Unlike GLP-1, promoting GIP action has been discredited as a viable therapeutic strategy for T2D, primarily because of its reported resistance in certain human subjects and its presumed obesogenic propensity, as deduced from rodent loss-of-function phenotypic analyses....